Does Medicare Cover Weight Loss Medication in 2026?

Yes, Medicare now covers weight loss medication through the new Medicare GLP-1 Bridge program that launched July 2026. This marks the first time Medicare has covered anti-obesity medications, but coverage is limited to specific drugs and circumstances.

Medicare GLP-1 Bridge Program

Launch Date: July 1, 2026 Duration: 2-year pilot program through June 2028 Budget: $3.2 billion allocated for coverage Expansion: BALANCE comprehensive model starts 2027

What’s Covered Under the Bridge Program:

Covered Medication: Wegovy (semaglutide) only Copay Cap: $50/month maximum patient cost Prior Authorization: Required for all patients Provider Requirements: Must participate in Bridge program

Eligibility Requirements

Patient Criteria:

• BMI ≥35 with at least one obesity-related comorbidity, OR
• BMI ≥30 with documented cardiovascular disease
• Age 18+ (no upper age limit)
• Failed traditional weight loss methods
• Not currently on diabetes GLP-1 medication

Required Comorbidities:

• Type 2 diabetes
• High blood pressure
• Sleep apnea
• Cardiovascular disease
• Non-alcoholic fatty liver disease (NAFLD)

What’s NOT Covered Yet

Excluded Medications:

• Zepbound (tirzepatide)
• Ozempic for weight loss (off-label)
• Saxenda (liraglutide)
• Oral semaglutide
• Contrave, Qsymia (older weight loss drugs)

Coverage Gaps:

• BMI 30-34 without cardiovascular disease
• Patients under 18
• Weight loss medications for cosmetic purposes

Prior Authorization Process

Required Documentation:

1. BMI calculations from 3+ visits over 6 months
2. Comorbidity documentation with ICD-10 codes
3. Failed weight loss attempts: 6+ months of documented diet/exercise programs
4. Cardiovascular risk assessment if BMI 30-34
5. Provider attestation of medical necessity

Timeline:

• Initial review: 14 business days
• Appeals process: 30 days for standard, 72 hours for expedited

BALANCE Model (2027)

Starting January 2027, Medicare launches the comprehensive BALANCE model:

Expanded Coverage:

• All FDA-approved weight loss medications
• BMI threshold lowered to 30 (no comorbidities required)
• Comprehensive lifestyle intervention programs
• Nutritionist and behavioral health services

Enhanced Benefits:

• $25/month medication copay cap
• No prior authorization for participating providers
• Bundled lifestyle intervention services
• Real-world effectiveness monitoring

Cost Breakdown

Current Costs (Bridge Program):

• Patient pays: $50/month maximum
• Medicare pays: ~$1,250/month
• Total program cost: ~$1,300/month per patient

Projected 2027 Costs (BALANCE):

• Patient pays: $25/month maximum
• Bundled services: Included in monthly payment
• Additional savings: Reduced hospitalizations, diabetes complications

Geographic Availability

Bridge Program Coverage:

• Available in all 50 states
• Limited to Medicare Advantage plans initially
• Traditional Medicare coverage varies by MAC

Provider Participation:

• Must register with CMS Bridge program
• Complete quality reporting requirements
• Demonstrate obesity treatment experience

How to Access Coverage

Step 1: Verify Eligibility

• Confirm BMI and comorbidity requirements
• Check if your Medicare plan participates
• Verify provider participation in Bridge program

Step 2: Medical Documentation

• Schedule comprehensive obesity evaluation
• Document 6+ months of weight loss attempts
• Obtain all required prior authorization documentation

Step 3: Submit Prior Authorization

• Provider submits PA request with documentation
• Wait for approval (14 business days)
• Appeal if initially denied

Common Denial Reasons

• Insufficient BMI documentation
• Missing comorbidity diagnosis codes
• Inadequate documentation of failed weight loss attempts
• Provider not enrolled in Bridge program
• Patient already on diabetes GLP-1 medication

Medicare Supplement Considerations

Medigap Plans: Do not typically cover prescription drugs – need Part D Medicare Part D: Bridge program supplements Part D coverage Medicare Advantage: Many MA plans participate in Bridge program

State Medicaid Dual Coverage

Dual-eligible beneficiaries may have additional coverage options:

• State Medicaid may cover excluded medications — for example, TennCare added weight-loss GLP-1 coverage on August 1, 2025
• Lower copays possible through dual-eligible special needs plans (D-SNPs)
• Additional weight loss services through state programs

Future Outlook

2027 BALANCE Expansion: Full implementation of comprehensive weight loss benefit 2028 Program Review: CMS will evaluate effectiveness and consider permanent coverage Potential Changes: Coverage may expand to additional medications and populations

The Bridge program represents a significant shift in Medicare policy, acknowledging obesity as a serious medical condition requiring pharmaceutical intervention.

Medical disclaimer: This content is for informational purposes only and is not medical advice. Consult a licensed healthcare provider before starting any treatment.